Figure 2.

Cumulative incidence of ATE, according to ALK rearrangement status. Outcome events counted from 6 months prior study index to 5 years post-index. Index date defined as date of NSCLC diagnosis. Death considered as a competing risk. ALK, anaplastic lymphoma kinase; ATE, arterial thromboembolism.